COhort of antithrOmbotic Use and cLinical Outcomes in Patients With Atrial Fibrillation (COOL-AF) Phase 2
Key facts
- Where
- Bangkok, Chanthaburi, Chiang Mai, Chiang Rai, Chon Buri, Khon Kaen, Lampang, Nakhon Nayok, Nakhon Pathom, Nakhon Ratchasima, Nakhon Sawan, Nonthaburi, Pathum Thani, Phitsanulok, Phuket, Ratchaburi, Sakon Nakhon, Songkhla, Surat Thani, Surin, Ubon Ratchathani, and Udon Thani, ThailandSee the 33 sites
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 100 years old?
Source: NCT06396299, who can take part
Where in Thailand
- Bhumibol Adulyadej HospitalBangkok, ThailandTaking people
- Charoen Krung Pracha Rak HospitalBangkok, ThailandTaking people
- Faculty of Meddcine Siriraj Hospital, Mahidol UniversityBangkok, ThailandTaking people
- Faculty of Medicine Chulalongkorn UniversityBangkok, ThailandTaking people
- Faculty of Medicine Vajira Hospital, Navamindradhiraj UniversityBangkok, ThailandTaking people
- Faculty of Medicine, Ramathibodi Hospital, Mahidol UniversityBangkok, ThailandTaking people
- Phramongkutklao College of MedicineBangkok, ThailandNot yet recruiting
- Police General HospitalBangkok, ThailandNot yet recruiting
- Rajavithi HospitalBangkok, ThailandNot yet recruiting
- Prapokklao Hospital (Chanthaburi),Chanthaburi, ThailandNot yet recruiting
- Faculty of Medicine, Chiang Mai UniversityChiang Mai, ThailandTaking people
- Nakornping HospitalChiang Mai, ThailandNot yet recruiting
- Chiangrai Prachanukroh HospitalChiang Rai, ThailandNot yet recruiting
- Chonburi HospitalChon Buri, ThailandTaking people
- Queen Savang Vadhana Memorial HospitalChon Buri, ThailandTaking people
- Faculty of Medicine Khon Kaen UniversityKhon Kaen, ThailandTaking people
- Lampang HospitalLampang, ThailandNot yet recruiting
- Faculty of Medicine, HRH Princess Maha Chakri Sirindhorn Medical Center (MSMC) Srinakharinwirot UniversityNakhon Nayok, ThailandNot yet recruiting
- Golden Jubilee Medical CenterNakhon Pathom, ThailandNot yet recruiting
- Maharat Nakorn Ratchasima HospitalNakhon Ratchasima, ThailandTaking people
- Sawanpracharak HospitalNakhon Sawan, ThailandTaking people
- Central Chest Institute of ThailandNonthaburi, ThailandTaking people
- Faculty of Medicine, Thammasat University, Rangsit CampusPathum Thani, ThailandTaking people
- Buddhachinaraj HospitalPhitsanulok, ThailandNot yet recruiting
- Faculty of Medicine, Naresuan UniversityPhitsanulok, ThailandNot yet recruiting
- Vachira Phuket HospitalPhuket, ThailandTaking people
- Ratchaburi HospitalRatchaburi, ThailandTaking people
- Sakonnakhon HospitalSakon Nakhon, ThailandNot yet recruiting
- Faculty of Medicine, Prince of Songkla UniversitySongkhla, ThailandTaking people
- Suratthani HospitalSurat Thani, ThailandTaking people
- Surin HospitalSurin, ThailandTaking people
- Sunpasitthiprasong HospitalUbon Ratchathani, ThailandTaking people
- Udonthani HospitalUdon Thani, ThailandTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Mahidol University
- Trial code
- NCT06396299
- Record updated
- 9 May 2025
- Original description
Atrial fibrillation (AF) is a leading cause of cardiovascular mortality and morbidity. Asian patients with AF have a higher rate of major bleeding including intracranial hemorrhage (ICH) compared to non-Asians. Non-vitamin K antagonist oral anticoagulants (NOACs) are the safer drugs compared to warfarin due to a lower rate of ICH, but the rate of NOACs use in many Asian AF is much lower than non-Asian countries due to economic concerns. The purpose of the COhort of antithrOmbotic use and cLinical outcomes in patients with Atrial Fibrillation (COOL-AF) Phase 2 registry is to determine the changes in antithrombotic patterns and the impact on clinical outcomes.Read full original descriptionShow less
Atrial fibrillation (AF) is a leading cause of cardiovascular mortality and morbidity. Asian patients with AF have a higher rate of major bleeding including intracranial hemorrhage (ICH) compared to non-Asians. Non-vitamin K antagonist oral anticoagulants (NOACs) are the safer drugs compared to warfarin due to a lower rate of ICH, but the rate of NOACs use in many Asian AF is much lower than non-Asian countries due to economic concerns. The purpose of the COhort of antithrOmbotic use and cLinical outcomes in patients with Atrial Fibrillation (COOL-AF) Phase 2 registry is to determine the changes in antithrombotic patterns and the impact on clinical outcomes.
The COOL-AF Phase 2 study is a prospective observational multicenter study of patients with known or newly diagnosed non-valvular AF in Thailand. The aim is a sample size is 3680 patients from 33 centers within a 2-years enrollment timeline. Patients will be follow-up every 6 months until 3 years. The study outcomes were death, ischemic stroke/systemic embolism, major bleeding, myocardial infarction, heart failure, and quality of life.
Inclusion: Participants aged 18 years and older with atrial fibrillation diagnosed based on a 12-lead ECG or ECG tracing from ambulatory ECG monitoring.
Exclusion: Patients who have experienced an ischemic stroke within the past 3 months before enrollment; Patients with a mechanical prosthetic heart valve; Patients expected to have a life expectancy of less than 3 years due to other diseases, such as cancer or AIDS, as determined from medical records; Patients with a platelet count less than 100,000/mm3 or who have myeloproliferative disorders (essential thrombocythemia, chronic myeloid leukemia, polycythemia vera, agnogenic myeloid metaplasia), hyperviscosity syndrome, chronic disseminated intravascular coagulation (DIC), or antiphospholipid syndrome; Patients with rheumatic mitral stenosis; Patients participating in research projects with concealed treatments; Pregnancy; Patients unable to follow the treatment plan; Patients who do not consent to participate in the study; Patients who are hospitalized or discharged from the hospital within the past 1 month.Contact/Locations.